

MDHHS – MCIR Release Notes

Version 2023 – MCIR OLTP 2023 9.9.0 – RFC 225206

Release Date: September 27, 2023

Forecasting & Assessment – 11 Items

1. PCV20 after completion of PCV13 and PPSV23 after age 65 should be complete (Ref#2481)

| Series | Immunizations | | | | Other | | Status |
|--------------------|---|--|---|--------|--------|---------|-----------------|
| | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | Dose 6+ | |
| Pneumococcal Adult | 03/20/2017 PPSV23 (Pneumovax) 87yrs 2mos | 03/20/2018 PCV13 (Prevnar13) 88yrs 2mos | 03/20/2023 PCV20 (Prevnar 20) 93yrs 2mos | | | | Series Complete |

| Personal Information/Status | | | | | |
|-----------------------------|--------------------|--------|-------------------|---|---------|
| Name | | DOB | | | |
| Patient ID | | Age | 93 Years 8 Months | Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated. | |
| Administered Vaccine | Can be given today | Dose # | Accelerated | Recommended | Overdue |
| Pneumococcal | Series Complete | | | | |

2. Dose 3 of HepB is invalid if interval violation of 16 weeks between dose 1-dose 3, accept dose 4 if intervals are met (Ref# 2506)

| Series | Immunizations | | | | Other | | Status |
|-------------|---|---|--------------------------------------|--------|--------|---------|-----------------|
| | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | Dose 6+ | |
| Hepatitis B | 06/01/2019 Hep B (adult) 52yrs 7mos | 07/01/2019 Hep B (adult) 52yrs 8mos | 10/27/2019 Hep B (adult) 53yrs | | | | Series Complete |

| Personal Information/Status | | | | | |
|-----------------------------|--------------------|--------|--------------------|---|---------|
| Name | | DOB | | | |
| Patient ID | | Age | 56 Years 11 Months | Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated. | |
| Administered Vaccine | Can be given today | Dose # | Accelerated | Recommended | Overdue |
| Hepatitis B | Series Complete | | | | |

3. Forecast and evaluate updated COVID-19 vaccines for 6 months- 4 years (Ref #2581)

| Series | Immunizations | | | | Other | | Status |
|------------|---|---|---|---|--------|---------|--------------------------------------|
| | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | Dose 6+ | |
| SARS-CoV-2 | 01/01/2023 COVID-19 PFR-BNT 3mcg/0.2mL 3yrs exactly | 01/22/2023 COVID-19 PFR- BNT 3mcg/0.2mL 3yrs | 07/12/2023 COVID-19 PFR Bivalent 3mcg/0.2mL 3yrs 6mos | 09/25/2023 COVID-19 MOD 25 mcg 3yrs 8mos | | | Up-To-Date Next Due 11/20/2023 |

| Personal Information/Status | |
|-----------------------------|----------------------|
| Name | DOB |
| Patient ID | Age 3 Years 8 Months |

Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated.

| Administered Vaccine | Can be given today | Dose # | Accelerated | Recommended | Overdue |
|----------------------|--------------------|--------|-------------|-------------|------------|
| COVID-19 (Moderna) | | 5 | 11/20/2023 | 11/20/2023 | 11/20/2023 |

- Recommended COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised by COVID-19 vaccination history, September 15, 2023
 - <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-01>
- Timing, spacing, age transitions, and simultaneous administration. September 15, 2023
 - <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#timing-spacing-interchangeability>

4. Forecast and Evaluate updated Covid-19 vaccines for 5 through 11-year-olds (Ref #2582)

| Series | Immunizations | | | | Other | | Status |
|------------|--|--|--|--------|--------|---------|---|
| | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | Dose 6+ | |
| SARS-CoV-2 | 07/01/2022 COVID-19 MOD 50mcg 7yrs 6mos | 09/05/2022 COVID-19 MOD 25 mcg ped 7yrs 8mos | 07/31/2023 COVID-19 MOD Bivalent 10mcg/0.2mL 8yrs 6mos | | | | COVID-19 (Pfizer/Moderna) DUE NOW |

| Personal Information/Status | |
|-----------------------------|----------------------|
| Name | DOB |
| Patient ID | Age 8 Years 8 Months |

Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated.

| Administered Vaccine | Can be given today | Dose # | Accelerated | Recommended | Overdue |
|---------------------------|--------------------|--------|-------------|-------------|------------|
| COVID-19 (Pfizer/Moderna) | YES | 4 | 09/25/2023 | 09/25/2023 | 09/25/2023 |

5. Forecast and Evaluate COVID-19 vaccine administration for ages 12 years and older (Ref #2583)

| Series | Immunizations | | | | | Other | | Status |
|------------|--|--|--|---|--|---------|--|---|
| | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | Dose 6+ | | |
| SARS-CoV-2 | 01/28/2021 COVID-19 PFR 30 mcg 69yrs 8mos | 09/26/2021 COVID-19 PFR 30 mcg 70yrs 4mos | 04/13/2022 COVID-19 MOD 100 mcg 70yrs 10mos | 10/03/2022 COVID-19 MOD Bivalent 50mcg/0.5mL 71yrs 4mos | 04/21/2023 COVID-19 MOD Bivalent 50mcg/0.5mL 71yrs 10mos | | | COVID-19 (Pfizer/Moderna) DUE NOW |

| Personal Information/Status | | | |
|-----------------------------|--|-----|-------------------|
| Name | | DOB | |
| Patient ID | | Age | 72 Years 4 Months |

Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated.

| Administered Vaccine | Can be given today | Dose # | Accelerated | Recommended | Overdue |
|---------------------------|--------------------|--------|-------------|-------------|------------|
| COVID-19 (Pfizer/Moderna) | YES | 7 | 09/12/2023 | 09/12/2023 | 09/12/2023 |

6. Forecast and evaluate CVX 303, 304, 305, 314 RSV vaccines for 60 years and older (Ref# 2518)

| Series Zostel | Immunizations | | | | | Other | | Status (Shingrix) DUE NOW |
|------------------|--|--------|--------|--------|--------|---------|--|---------------------------------|
| | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | Dose 6+ | | |
| RSV | 09/01/2023 RSV vaccine, unspecified 70yrs 11mos | | | | | | | Series Complete |

| Personal Information/Status | | | |
|-----------------------------|--|-----|--------------------|
| Name | | DOB | |
| Patient ID | | Age | 70 Years 11 Months |

Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated.

| Administered Vaccine | Can be given today | Dose # | Accelerated | Recommended | Overdue |
|----------------------|--------------------|--------|-------------|-------------|---------|
| RSV | Series Complete | | | | |

7. Forecast and evaluate for 0 to 8 months CVX 306 nirsevimab (Beyfortus) 0.5ml (Ref# 2565)

| Personal Information/Status | | | | | |
|-----------------------------|--------------------|--------|-------------|--|------------|
| Name | | DOB | | Assessment indicates that vaccinations can be administered today if not medically contraindicated. | |
| Patient ID | | Age | 11 Days | | |
| Administered Vaccine | Can be given today | Dose # | Accelerated | Recommended | Overdue |
| RSV | YES | 1 | 09/15/2023 | 09/15/2023 | 09/15/2023 |

- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
 - www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm

8. Forecast and evaluate for 8-19 months of age CVX 307 RSV nirsevimab (Beyfortus) 1ml (Ref# 2566)

| Series | Immunizations | | | | Other | | Status |
|--------|---|--|--------|--------|--------|---------|-----------------|
| | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | Dose 6+ | |
| RSV | 09/04/2023 RSV Nirsevimab(Beyfortus)0.5ml 1yr 2mos | 09/04/2023 RSV Nirsevimab(Beyfortus) 1 ml 1yr 2mos | | | | | Series Complete |

| Personal Information/Status | | | | | |
|----------------------------------|--------------------|--------|-----------------|---|---------|
| Name | | DOB | | Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated. | |
| Patient ID | | Age | 1 Year 3 Months | | |
| Administered Vaccine | Can be given today | Dose # | Accelerated | Recommended | Overdue |
| RSV nirsevimab (Beyfortus) 200mg | Series Complete | | | | |

9. Forecast and Evaluate updated Covid-19 vaccines for 5 through 11-year-olds (Ref # 2582)

| Series | Immunizations | | | | | Other | | Status |
|------------|--|--|--|--------|--------|---------|--|---|
| | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | Dose 6+ | | |
| SARS-CoV-2 | 07/01/2022 COVID-19 MOD 50mcg 7yrs 6mos | 09/05/2022 COVID-19 MOD 25 mcg ped 7yrs 8mos | 07/31/2023 COVID-19 MOD Bivalent 10mcg/0.2mL 8yrs 6mos | | | | | COVID-19 (Pfizer/Moderna) DUE NOW |

| Personal Information/Status | | | | | | |
|-----------------------------|--------------------|--------|------------------|-------------|------------|---|
| Name | | DOB | | | | Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated. |
| Patient ID | | Age | 8 Years 8 Months | | | |
| Administered Vaccine | Can be given today | Dose # | Accelerated | Recommended | Overdue | |
| COVID-19 (Pfizer/Moderna) | YES | 4 | 09/25/2023 | 09/25/2023 | 09/25/2023 | |

10. Forecast and Evaluate COVID-19 vaccine administration for ages 12 years and older (Ref# 2583)

| Series | Immunizations | | | | | Other | | Status |
|------------|---------------|--------|--------|--------|--------|---------|--|--------------------------------------|
| | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | Dose 6+ | | |
| SARS-CoV-2 | | | | | | | | Up-To-Date Next Due 11/09/2023 |

| Personal Information/Status | | | | | | |
|-----------------------------|--------------------|--------|-------------------|-------------|------------|---|
| Name | | DOB | | | | Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated. |
| Patient ID | | Age | 12 Years 4 Months | | | |
| Administered Vaccine | Can be given today | Dose # | Accelerated | Recommended | Overdue | |
| COVID-19 (Pfizer/Moderna) | | 4 | 11/09/2023 | 11/09/2023 | 11/09/2023 | |

11. Add CVX 314 RSV vaccine unspec. and 315 RSV MAB, unspec, update name of CVX 304 (Ref# 2593)

Add to Historical

1. CVX 314 RSV vaccine, unspecified
 2. CVX 315 RSV MAB unspecified
 3. **Change** existing code CVX 304 to RSV, unspecified
- Respiratory Syncytial Virus (RSV) Codes and Crosswalks
 - <https://www.cdc.gov/vaccines/programs/iis/code-sets.html#rsv>

General – 4 Items

1. Ending Inventory Report displaying incorrect values (Ref# 2478)

- Prior to Release: 24 Unusable is incorrect

| Lot Number | Expiration Date | Begin Balance | Doses In | Doses Out | Admins | Brwd/Rplcd | Unusable LW | Balance | Dose Count | Diff |
|------------|-----------------|---------------|----------|-----------|--------|------------|-------------|---------|------------|------|
| AS3617B | 06/30/2023 | 24 | 0 | 0 | 0 | 0 | 24 | 0 | 0 | 0 |
| TOTAL | | 24 | 0 | 0 | 0 | 0 | 24 | 0 | 0 | 0 |

- Post Release: 20 Unusable and 4 Dose Out is correct

| Lot Number | Expiration Date | Begin Balance | Doses In | Doses Out | Admins | Brwd/Rplcd | Unusable LW | Balance | Dose Count | D |
|------------|-----------------|---------------|----------|-----------|--------|------------|-------------|---------|------------|---|
| AS3617B | 06/30/2023 | 24 | 0 | 4 | 0 | 0 | 20 | 0 | 0 | |
| TOTAL | | 24 | 0 | 4 | 0 | 0 | 20 | 0 | 0 | |

2. HL7 Vaccine Fund Eligibility Error on new COVID vaccines (Ref# 2594)

- **Issue:** HL7 erroring messages with new Covid CVX codes
- **Resolution:** HL7 now accepts messages with new Covid CVX codes

3. HL7 VXU for Minors must have a Responsible Party (Ref# 1293)

- **Issue:** If a minor's VXU data is processed through HL7 intake for the first time, and that data did not contain information to designate a responsible party, MCIR accepts the message with no warning of the issue.
- **Resolution:** Minors must have a responsible party designated on HL7 VXU messaging. When MCIR receives a patient's VXU for a minor, a Next of Kin with a "responsible" relationship type should be present on the message. If not present, a warning will be issued, the information will be accepted.

4. HL7 process does not save Race = UNK (Ref# 2470)

- **Issue:** HL7 contains Race=UNK, the patients record does not contain UNK for race
- **Resolution:** HL7 process updated to the patient's record will reflect UNK for race

Help Desk – 10 Items

If you have questions or need assistance, please contact your Field Representative, MCIR Region, or **MCIR SOM Help Desk at** MDHHS-MCIRHelp@michigan.gov.